肝素涂层透析器联合枸橼酸透析液无全身抗凝的透析器性能:EvoCit随机交叉非劣效研究
EvoCit研究为单中心随机交叉非劣效试验,纳入26例维持性血透患者共617次透析,比较肝素涂层透析器联合1.0mmol/L枸橼酸透析液无全身抗凝(EvoCit)与肝素涂层透析器联合全身肝素(EvoHep)的透析器性能。主要终点Kt/Vurea差异为-0.03(95%CI -0.06至-0.007),达到非劣效;但EvoCit组提前终止透析比例更高、凝血酶生成增加、透析器血室容积下降更明显。
要点
- EvoCit方案在Kt/Vurea、尿素下降率和β2微球蛋白下降率上非劣于EvoHep。
- EvoCit组4.2%的透析次数因提前终止而缩短,EvoHep组无提前终止。
- EvoCit组凝血酶生成增加且透析器血室容积下降更明显,提示膜凝血增加。
核心结论
- EvoCit在溶质清除方面非劣于EvoHep,但导致更多提前终止透析、更多膜凝血和更多凝血酶生成。
研究设计与样本
- 随机交叉非劣效试验,非劣效界值为主要终点差异≤10%。
- 单中心26例维持性血透患者,共617次透析,随机先接受4周EvoCit或EvoHep再交叉4周。
主要发现
- EvoCit与EvoHep的Kt/Vurea估计差异为-0.03(95%CI -0.06至-0.007),EvoCit平均Kt/Vurea为1.47±0.05(SE),EvoHep为1.50±0.05。
- 尿素和β2微球蛋白下降率亦达到非劣效。
- EvoCit组6例患者中4.2%的透析次数需提前终止,EvoHep组无提前终止。
- EvoCit有效治疗时间为236±5分钟,EvoHep为238±1分钟。
- EvoCit后凝血酶生成增加且透析器血室容积下降更明显。
临床怎么用
- 在需要避免全身抗凝的血透患者中,EvoCit可作为保留溶质清除的选项,但需警惕提前终止透析和膜凝血风险。
局限性
- 未评估避免全身抗凝对临床结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: The EvoCit study was designed to evaluate performance of a heparin-grafted dialyzer during hemodialysis with and without systemic anticoagulation. STUDY DESIGN: Randomized, crossover, noninferiority trial. Noninferiority was defined as a difference of≤10% for the primary outcome. SETTING & PARTICIPANTS: Single hemodialysis center; 26 prevalent patients treated with 617 hemodialysis sessions. INTERVENTIONS: Hemodialysis using a heparin-grafted dialyzer combined with a 1.0mmol/L citrate-enriched dialysate ("EvoCit") without systemic anticoagulation compared with hemodialysis performed with a heparin-grafted dialyzer with systemic heparin ("EvoHep"). Patients were randomly allocated to a first period of 4 weeks and crossed over to the alternative strategy for a second period of 4 weeks. OUTCOMES: The primary end point was the difference in Kt/Vurea between EvoCit and EvoHep. Secondary end points were urea reduction ratio, middle molecule removal, treatment time, thrombin generation, and reduction in dialyzer blood compartment volume. RESULTS: The estimated difference in Kt/Vurea between EvoCit and EvoHep was-0.03 (95% CI, -0.06 to-0.007), establishing noninferiority with mean Kt/Vurea of 1.47±0.05 (SE) for EvoCit and 1.50±0.05 for EvoHep. Noninferiority was also established for reduction ratios of urea and β2-microglobulin. Premature discontinuation of dialysis was required for 4.2% of sessions among 6 patients during EvoCit and no sessions during EvoHep. Effective treatment time was 236±5 minutes for EvoCit and 238±1 minutes for EvoHep. Thrombin generation was increased and there was greater reduction in dialyzer blood compartment volume after treatments with EvoCit compared with EvoHep. LIMITATIONS: The effects of avoiding systemic anticoagulation on clinical outcomes were not evaluated. CONCLUSIONS: EvoCit is noninferior to EvoHep with respect to solute clearance but results in a greater number of shortened treatments, more membrane clotting, and greater thrombin generation TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03887468.
引用
- François K, De Clerck D, Tonnelier A, et al. Dialyzer Performance During Hemodialysis Without Systemic Anticoagulation Using a Heparin-Grafted Dialyzer Combined With a Citrate-Enriched Dialysate: Results of the Randomized Crossover Noninferiority EvoCit Study. Am J Kidney Dis. 2021. PMID: 33940113. doi:10.1053/j.ajkd.2021.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。